Literature DB >> 23672497

Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion.

Weixian Xu1, Zhiguo Guo, Lin Mi, Guisong Wang.   

Abstract

The study was to investigate the association of endogenous erythropoietin (EPO) and coronary collateral development. Forty-nine patients (31 with chronic total occlusion (CTO), 18 with normal coronary artery) were consecutively enrolled. The serum EPO was positively related with Rentrop class. Increased serum EPO was one of the independent predictors of good collateral development (odds ratio 1.31; p = 0.025). A significantly positive correlation was seen between serum EPO and vascular endothelial growth factor (VEGF) levels (r = 0.96, p < 0.001). Circulatory EPO may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23672497     DOI: 10.3109/1354750X.2013.787459

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  6 in total

1.  Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia.

Authors:  Weixian Xu; Haiyi Yu; Weihong Li; Wei Gao; Lijun Guo; Guisong Wang
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

2.  Impact of serum erythropoietin level on collateral vessel development in patients with coronary artery disease.

Authors:  Nil Özyüncü; Sadi Güleç; Çağdaş Özdöl; Başar Candemir; Aydan Ongun; Cansın Tulunay Kaya; Çetin Erol
Journal:  Anatol J Cardiol       Date:  2017-03-09       Impact factor: 1.596

3.  Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion.

Authors:  Qing Qin; Juying Qian; Jianying Ma; Lei Ge; Junbo Ge
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 4.  Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial.

Authors:  Catalina Balaguer; Alejandro Peralta; Ángel Ríos; Amanda Iglesias; Josep Lluís Valera; Aina Noguera; Joan B Soriano; Àlvar Agustí; Ernest Sala-Llinas
Journal:  Contemp Clin Trials Commun       Date:  2016-01-14

5.  Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion.

Authors:  I O Yuksel; G Cagirci; E Koklu; A Yilmaz; S Kucukseymen; H Y Ellidag; S Cay; N Yilmaz; S Arslan
Journal:  Neth Heart J       Date:  2016-10       Impact factor: 2.380

6.  The Erythropoetin rs1617640 Gene Polymorphism Associates with Hemoglobin Levels, Hematocrit and Red Blood Cell Count in Patients with Peripheral Arterial Disease.

Authors:  Wilfried Renner; Melanie Kaiser; Sebastian Khuen; Olivia Trummer; Harald Mangge; Tanja Langsenlehner
Journal:  Genes (Basel)       Date:  2020-11-04       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.